Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
NCT02499978 · Stanford University · PHASE2/PHASE3 · withdrawn · last registry update 2021-07-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP3A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-10Results posted on the registry: University of California, Los Angeles, Switch to E/C/FTC/TAF daily (NCT03251144)
- 2022-04-19Results posted on the registry: Kenneth H. Mayer, MD, Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) (NCT01855867)
- 2022-01-03Results posted on the registry: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy (NCT02859558)
- 2021-08-13Results posted on the registry: Emory University, Genvoya (NCT03976752)
- 2021-05-24Results posted on the registry: Gilead Sciences, E/C/F/TAF + E/C/F/TAF (Low Dose) (NCT01854775)
- 2021-02-11Results posted on the registry: University of Colorado, Denver, TDF with a boosted protease inhibitor + TAF with a boosted protease inhibitor (NCT03126370)
- 2021-01-14Also stopped (withdrawn): Azienda Ospedaliero-Universitaria di Parma, Oxytocin + Standard of Care (NCT04386447)
- 2020-12-04Phase 3 first posted: Chelsea and Westminster NHS Foundation Trust, Biktarvy + Symtuza (NCT04653194)
- 2020-11-06Also stopped (terminated): Giovanni Di Perri, emtricitabine, darunavir/cobicistat, maraviroc (NCT03163277)
- 2020-08-27Results posted on the registry: Gilead Sciences, B/F/TAF + NRTIs (NCT03631732)
- 2020-07-17Phase 3 first posted: University of Rome Tor Vergata, liposomal lactoferrin + SOC therapy (NCT04475120)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision